Bengaluru: Johnson & Johnson (J & J) said on Tuesday that it was in talks with the Indian government to explore ways to accelerate the delivery of the Single Covid-19 vaccine in the country.
The company also said according to the recent announcement by Indian drug regulators, there is no need for bridging clinical trials from vaccines in India.
The US-based company said in April it was seeking approval to conduct clinical studies bridging from Janssen Covid-19 vaccine candidate in India.
However, in May, the country canceled a local trial for the “established” vaccine produced in other countries.
Meanwhile, an NGO, the Association of Health Service Providers (AHPI), said that it planned to get 100 million doses of Johnson-& Johnson vaccine from the European Union (EU) to be provided in India.
“We as NGOs represent most hospitals and have given a letter of intent to have 100 million doses for India.
Currently being processed,” said Director General of Ahpi, said Dr.
Girdhar Gyani.
Discussion about speeding up shipping vaccines: J & J
